Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar;102(2):e140-e155.
doi: 10.1111/aos.15725. Epub 2023 Jun 23.

How latanoprost changed glaucoma management

Maria Francesca Cordeiro  1   2   3 , Stefano Gandolfi  4 , Konstantin Gugleta  5 , Eduardo M Normando  3 , Francesco Oddone  6
Affiliations
Free article
Review

How latanoprost changed glaucoma management

Maria Francesca Cordeiro et al. Acta Ophthalmol. 2024 Mar.
Free article

Abstract

Glaucoma is currently considered one of the leading causes of severe visual impairment and blindness worldwide. Topical medical therapy represents the treatment of choice for many glaucoma patients. Introduction of latanoprost, 25 years ago, with an entirely new mechanism of action from that of the antiglaucoma drugs used up to that time was a very important milestone. Since then, due mainly to their efficacy, limited systemic side effects and once daily dosing, prostaglandin analogues (PGAs) have become as the first-choice treatment for primary open-angle glaucoma. PGAs are in general terms well tolerated, although they are associated with several mild to moderate ocular and periocular adverse events. Among them, conjunctival hyperemia, eyelash changes, eyelid pigmentation, iris pigmentation and hypertrichosis around the eyes are the most prevalent. The objective of this paper is to review the role of PGAs in the treatment of glaucoma over the 25 years since the launch of Latanoprost and their impact on clinical practice outcomes.

Keywords: Latanoprost; glaucoma; medical treatment; open-angle glaucoma; progression; prostaglandin analogues.

PubMed Disclaimer

References

REFERENCES

    1. Abramovitz, M., Adam, M., Boie, Y., Carrière, M., Denis, D., Godbout, C. et al. (2000) The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochimica et Biophysica Acta, 1483(2), 285-293.
    1. Abrams, D.A., Robin, A.L., Pollack, I.P., DeFaller, J.M. & DeSantis, L. (1987) The safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers. Archives of Ophthalmology, 105(9), 1205-1207.
    1. Akarsu, C., Bilgili, Y.K., Taner, P., Unal, B. & Ergin, A. (2004) Short-term effect of latanoprost on ocular circulation in ocular hypertension. Clinical & Experimental Ophthalmology, 32(4), 373-377.
    1. Alagoz, G., Gürel, K., Bayer, A., Serin, D., Celebi, S. & Kukner, S. (2008) A comparative study of bimatoprost and travoprost: effect on intraocular pressure and ocular circulation in newly diagnosed glaucoma patients. Ophthalmologica, 222(2), 88-95.
    1. Allemann, R., Flammer, J. & Haefliger, I.O. (2003a) Vasoactive properties of bimatoprost in isolated porcine ciliary arteries. Klinische Monatsblätter für Augenheilkunde, 220(3), 161-164.

MeSH terms

Grants and funding

LinkOut - more resources